1601. Combination Therapy versus Monotherapy for Carbapenem-resistant Organisms: Is More Really Better?

BACKGROUND: Carbapenem-resistant organisms (CROs) represent an urgent public health threat and associated with mortality rates up to 60%. Pharmacotherapy for these infections remain challenging and historically included multiple agents. Meropenem/vaborbactam and ceftazidime/avibactam are options to...

Descripción completa

Detalles Bibliográficos
Autores principales: Najia, Laila, Carr, Amy, Alexander, Jose, Minor, Sarah B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778249/
http://dx.doi.org/10.1093/ofid/ofaa439.1781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778249/
http://dx.doi.org/10.1093/ofid/ofaa439.1781

Ejemplares similares